← back to search

Cuiying Zhang

Harbin Medical University · CN
Area of research
Molecular Biology · Food Science
Research interest
Research focused on Metabolic engineering and Yarrowia, with related work in Biochemical engineering, Synthetic biology, Lung cancer. Notable publications include 'Simultaneous Improvement of Limonene Production and Tolerance in Yarrowia lipolytica through Tolerance Engineering and Evolutionary Engineering', 'Hybrid promoter engineering strategies in Yarrowia lipolytica: isoamyl alcohol production as a test study', and 'Metabolic engineering of microbes for monoterpenoid production'.
h-index
citations
339
works
14
NIH funding
primary concept
email

Recent publications

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial
CA A Cancer Journal for Clinicians 2025cited by 2position: middledoi
Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study
Chinese Medical Journal 2025cited by 1position: middledoi
Biosynthesis of α-bisabolene from low-cost renewable feedstocks by peroxisome engineering and systems metabolic engineering of the yeast <i>Yarrowia lipolytica</i>
Green Chemistry 2023cited by 39position: middledoi
Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study
Journal of Cancer Research and Clinical Oncology 2023cited by 9position: middledoi
Characteristics and survival analysis of breast cancer survivors with metachronous double primary cancers: a retrospective cohort study
Translational Cancer Research 2023cited by 3position: middledoi
Data from Routine-Dose and High-Dose Icotinib in Patients with Advanced Non–Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial
2023cited by 0position: middledoi
Analyzing the multi-target pharmacological mechanism of folium Artemisia argyi acting on breast cancer: a network pharmacology approach
Annals of Translational Medicine 2022cited by 5position: middledoi
Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort
Translational Lung Cancer Research 2022cited by 4position: middledoi
Simultaneous Improvement of Limonene Production and Tolerance in <i>Yarrowia lipolytica</i> through Tolerance Engineering and Evolutionary Engineering
ACS Synthetic Biology 2021cited by 77position: middledoi
Hybrid promoter engineering strategies in Yarrowia lipolytica: isoamyl alcohol production as a test study
Biotechnology for Biofuels 2021cited by 54position: middledoi
Metabolic engineering of microbes for monoterpenoid production
Biotechnology Advances 2021cited by 53position: middledoi
Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection: a randomized trial
Signal Transduction and Targeted Therapy 2021cited by 41position: middledoi
Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in <scp>China</scp>
Thoracic Cancer 2021cited by 39position: middledoi
Next-generation metabolic engineering of non-conventional microbial cell factories for carboxylic acid platform chemicals
Biotechnology Advances 2020cited by 40position: middledoi
Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial
Annals of Translational Medicine 2020cited by 13position: middledoi
Protective effects of emodin on lung injuries in rat models of liver fibrosis
Open Life Sciences 2019cited by 3position: middledoi
Transplantation of HGF gene-engineered skeletal myoblasts improve infarction recovery in a rat myocardial ischemia model
PLoS ONE 2017cited by 19position: middledoi
Expression of the 78 kD glucose-regulated protein is induced by endoplasmic reticulum stress in the development of hepatopulmonary syndrome
Gene 2013cited by 7position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 5 papers (2020–2023)Aiqun Yu · National University of Singapore5 papers (2020–2023)Jee Loon Foo · National University of Singapore5 papers (2020–2023)Yu Zhao · Hebei General Hospital3 papers (2020–2021) · 3 papers (2020–2021)Zhihui Lu · Guangxi University3 papers (2021–2023) · 3 papers (2013–2019) · 3 papers (2021–2023)Jian Li · Xinjiang University2 papers (2020–2021)Yue Yang · Nanchang University2 papers (2022–2023)Xiuli Wang · Jilin University2 papers (2022–2023)Yimin Fan · Shanxi Medical University2 papers (2013–2019)Cheng Ji · Union Hospital2 papers (2013–2019)Han De-wu · Shanxi Medical University2 papers (2013–2019)Cuimin Ding · State Key Laboratory of Solidification Processing2 papers (2023–2025)Yan Wang · Xi'an Jiaotong University2 papers (2023–2025)Jinlu Wang · Harbin Medical University2 papers (2022–2023)Shenglong Li · Nantong University2 papers (2020–2021)Adison Wong · National University of Singapore2 papers (2021–2023)Xingjian Niu · Harbin Medical University2 papers (2022–2023)